Valion Bio, Inc. Income Statement
VBIO|3 years of annual SEC 10-K data (FY2022-FY2024)
Line items include revenue, cost of goods sold, gross profit, operating expenses, interest, taxes, and net income with per-share data across 3 fiscal years. All figures from audited SEC 10-K filings.
Valion Bio, Inc. reported $1M in revenue and $8M in net loss for FY2024. Revenue has declined at a 3.3% compound annual rate over the past 2 years.
Based on SEC 10-K filings.
Key Data Points
- Altman Z-Score -10.05 (distress zone, below 1.8 threshold)
- Low earnings quality (accrual-heavy earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
| Item | FY2024 | FY2023 | FY2022 |
|---|---|---|---|
| Revenue | $1.2M | $1.8M | $1.3M |
| Cost of Revenue | $889.0K | $1.5M | $1.3M |
| Gross Profit | $287.0K | $299.0K | -$38.0K |
| SG&A Expense | $4.8M | $5.9M | $2.9M |
| R&D Expense | $1.7M | $1.7M | $878.0K |
| Operating Income | -$8.2M | -$10.1M | -$5.6M |
| Interest Expense | $1.0K | $2.0K | -$1.8M |
| Net Income | -$8.2M | -$10.1M | -$8.5M |
| EPS (Basic) | -$176.80 | -$104.32 | -$2.43 |
| EPS (Diluted) | -$176.80 | -$104.32 | -$2.43 |
| Shares Outstanding | 86.2K | 96.8K | 9.7M |
| Gross Margin | 24.4% | 16.3% | -3.0% |
| Operating Margin | -701.1% | -548.8% | -448.1% |
| Profit Margin | -701.0% | -548.7% | -675.7% |